KQ-2003 CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
KQ-2003 CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
Will this trial show a positive result on objective response rateOutcome measureObjective Response Rate (ORR)Objective response rate is the share of patients whose tumors shrink by a predefined amount. It is useful for early signals and accelerated approval settings, but it is more surrogate than survival outcomes.ClinicalTrials.gov outcome?
Paper Trading
Create account to trade- Primary Completion
- 3/31/26
- Study Completion
- 3/31/26
- Sponsor
- Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
- Ticker
- Unavailable
- Type
- Trial Status
- Unknown; last known recruiting
- Trial Size
- 29
- NCT
- NCT06223646
- Trial Description
- This study tests KQ-2003 CAR-T cells in adults with relapsed or refractory multiple myeloma, mainly measuring serious early side effects and dose selection.